SCHEMBL3607360

SCHEMBL3607360

[NH]c1cccc2c1NC(=O)C(N1CCC(O)CC1)C2

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.37
DRD2 P14416 1/20 0.37
DRD4 P21917 1/20 0.37
MEN1 O00255 1/20 0.37
APEX1 P27695 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ALDH1A1 P00352 3/20 0.36
CRBN Q96SW2 2/20 0.35
RAB9A P51151 1/20 0.35
HSD11B1 P28845 1/20 0.33
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
OPRK1 P41145 1/20 0.32
OPRL1 P41146 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
MAPT P10636 1/20 0.32
TSHR P16473 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3592416 0.93 CRBN (0.36) KMT2ADRD2DRD4MEN1APEX1
SCHEMBL3595636 0.85 TSHR (0.46) KMT2ADRD2DRD4TDP1ALDH1A1
SCHEMBL3607361 0.85 MEN1 (0.40) KMT2ADRD2DRD4MEN1APEX1
SCHEMBL3604098 0.84 DRD2 (0.39) KMT2ADRD2DRD4ALDH1A1CRBN
SCHEMBL3593849 0.84 DRD2 (0.41) DRD2DRD4TDP1ALDH1A1CRBN
SCHEMBL3599720 0.84 DRD2 (0.39) KMT2ADRD2DRD4ALDH1A1CRBN
SCHEMBL3599654 0.84 DRD2 (0.35) KMT2ADRD2DRD4MEN1APEX1
SCHEMBL3590132 0.84 CRBN (0.37) KMT2ADRD2DRD4MEN1APEX1
SCHEMBL3594128 0.83 POLB (0.39) KMT2ADRD2DRD4MEN1ALDH1A1
SCHEMBL3597119 0.83 ALDH1A1 (0.39) KMT2ADRD2DRD4MEN1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2010-01-21 US disclosed
EP-2128157-A1 HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2009-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016285-A1 HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE CCNY, CCND3, NSD3 KMT2A 906/4885DRD2 530/4885DRD4 795/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.